Use of Venetoclax in Newly Diagnosed Acute Myeloid Leukemia (AML)

Courtney DiNardo, MD, discusses the use of venetoclax in newly-diagnosed acute myeloid leukemia, with a review of data from the VIALE-A clinical trial.

EP. 1: Treatment Options for Newly-Diagnosed AML

June 22nd 2022

Courtney DiNardo, MD, describes how the treatment options for patients with newly diagnosed acute myeloid leukemia differs for patients under and over 60 years of age.

EP. 2: The VIALE-A Trial: Venetoclax plus Azacitidine in AML Treatment

June 22nd 2022

Dr Courtney DiNardo reviews the efficacy data from the VIALE-A trial and explains the rationale for combining venetoclax with azacitidine as a treatment option for patients with AML.

EP. 3: Dose Management for Venetoclax plus Azacitidine

June 22nd 2022

Dr Courtney DiNardo details the dosing recommendations for venetoclax plus azacitidine and the importance of bone marrow assessments.

EP. 4: Safety Outcomes from the VIALE-A Trial

June 22nd 2022

A review of the safety outcome data of venetoclax plus azacitidine from the VIALE-A trial.

EP. 5: Unmet Needs of AML and Advice for Community Oncologists

June 22nd 2022

Courtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.